CD14 and neoplasm: Drugs were well tolerated and the treatment significantly decreased tumor‐infiltrating CD14+ monocytes, which are associated with tumor progression and metastatic disease, and reduced markers of epithelial‐to‐mesenchymal transition (EMT), reducing the pro‐metastatic capacity of the malignant tissue.